# Oliver Sartor

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/oliver-sartor/

## Facts

| Field | Value |
| --- | --- |
| Citations | 45,927 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 97 |
| i10-index | 428 |
| Last Known Institution | Mayo Clinic in Arizona |
| OpenAlex ID | https://openalex.org/A5073246821 |
| ORCID iD | https://orcid.org/0000-0002-8777-7343 |
| Works | 1,262 |

## Researcher papers

- [Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial](https://scholariq.org/papers/prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant/)
- [Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer/)
- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)
- [Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3](https://scholariq.org/papers/trial-design-and-objectives-for-castration-resistant-prostate-cancer-updated/)
- [Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group](https://scholariq.org/papers/eligibility-and-response-guidelines-for-phase-ii-clinical-trials-in-androgen/)
- [Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/survival-with-olaparib-in-metastatic-castration-resistant-prostate-cancer/)
- [Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-the-report-of-the-advanced/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data](https://scholariq.org/papers/prediction-of-overall-survival-for-patients-with-metastatic-castration-resistant/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)

## Researcher university

- [Mayo Clinic in Arizona](https://scholariq.org/institutions/mayo-clinic-in-arizona/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.